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ABSTRACT
INTRODUCTION: Erysipelas is a common, ubiquitous bacterial infection of the skin mainly caused by 
Streptococcus pyogenes - group A beta-hemolytic streptococcus. The current epidemiology of the disease 
demonstrates an upward trend in cases with primary and recurrent erysipelas, a change in the site of 
predilection – from face to lower limbs, and an increase of severe cases with a hemorrhagic or bullous-
hemorrhagic component. To date, the alterations in hemostasis due to streptococcal bacterial infection are 
still not well defined. Despite the advanced treatment of erysipelas, in approximately 10% of patients with 
hemorrhagic and bullous-hemorrhagic erysipelas, a skin necrosis has occurred. The combination of severe 
types of erysipelas with local and general predisposing factors such as diabetes mellitus, obesity, chronic 
vessel insufficiency results in recurrences and complications with high percentage of disability. In addition, 
streptococcal infections may have fulminant progression as for every 1 hour delay of adequate treatment, 
the percent of mortality increases with 7.5%. 
AIM: The purpose of this paper is to establish the current concepts and observations of hemostatic changes 
in erysipelas.
MATERIALS AND METHODS: Literature referred in MEDLINE, Web of Science, Scopus has been 
studied.
RESULTS: The hemostasis changes in erysipelas are not well researched. The available literature is 
insufficient as the studies are based on a small number of patients, which prevents any significant conclusions. 
CONCLUSION: The increasing incidence of patients with severe form of erysipelas stresses the need to 
intensify the study of hemostasis in erysipelas. Knowing the mechanisms of coagulation changes might help 
to predict and prevent severe, irreversible complications. 
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INTRODUCTION
Erysipelas is a common, acute or chronic (re-
current) infection of the skin affecting the superfi-
cial dermis and hypodermis, lymph vessels, and pe-
ripheral lymph nodes. The disease is mainly caused 
by Streptococcus pyogenes, rarely by other etiological 
agents such as St. aureus, Str. pneumoniae, Kl. pneu-
moniae, E. coli (1-3).
Group A beta-hemolytic streptococcus is an 
obligatory human pathogen. It comprises a hyal-
uronic capsule, a superficial protein layer, a middle 
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plasma fibrinogen and GPIIb/IIIa platelet receptors 
and tissue factor expression. Tissue factor is the most 
powerful molecule affecting coagulation cascade 
(13). The aim of coagulation involvement during in-
flammatory response is fibrin clotting and S. pyo-
genes entrapment. Nevertheless, S. pyogenes has de-
veloped an evolutionary strategy to escape hemostat-
ic system defense by producing fibrinolytic enzyme - 
streptokinase (14). Once started, the fibrinolysis en-
ables pathogen invasion and dissemination (15).
The Physiology of Coagulation
Hemostasis works through a dynamic balance 
between procoagulant and anticoagulant mecha-
nisms of the body. It consists of three main parts, 
structurally and functionally connected – a vascu-
lar wall, plasma systems - coagulation, fibrinoly-
sis, kallikrein-kinin and complement - and cellu-
lar elements – mainly platelets (16-18). In 1960, Da-
vie, Ratnoff and Macfarlane presented a schemat-
ic model of the coagulation system. They postulat-
ed the so-called “cascade” theory, and according to it 
there are two pathways of hemostasis activation - in-
trinsic pathway of coagulation (contact system) and 
extrinsic pathway of coagulation (tissue factor - de-
pendent) (15,19) (Fig. 2). This is an illustrative model 
and is only valid in vitro (16). Hemostasis develops in 
three phases and is subdivided into primary and sec-
ondary hemostasis. The pathological alterations may 
affect every phase, part or division of the hemosta-
sis (20,21). 
Pathophysiology of Coagulation in Erysipelas 
Coagulation has three phases (15):
1. Alteration in the first phase of hemostasis – 
hypercoagulation, acoagulability, hemor-
rhagic syndrome
polysaccharidic layer, and an inner peptidoglycan 
layer. The basic factor of virulence – the so-called M-
protein - is able to inhibit the microbial phagocytosis 
(4, 5). Similarly, polysaccharide A has a toxic effect on 
cells. Peptidoglycans are cardiotoxic, pyrogenic and 
have a thrombolytic effect on human tissues. What 
is more, S. pyogenes has a huge number of enzymes 
among which are erythrogenic toxin, О-/S –strepto-
lysins, streptokinase, proteinase, esterase, amylase, 
hemolysin, САМР-factor, DNA-ase, hyaluronidase, 
complement inhibitors, cysteine protease, endo-β-
N-acetylglucozaminidase, superoxide dismutase and 
immunoglobulin-destructing enzymes (6-10). 
During erysipelas, structural and functional 
components of the causative agent get into interac-
tion with the host resulting in an alteration of some 
coagulation indices. The reactivity of the hemostatic 
system is explained by the common origin of the he-
mostatic and immune system and has the aim to lim-
it the spreading of an infectious agent and to help its 
elimination. As a response to a given infectious agent, 
the immune system generates an immune response, 
mediated by procoagulant substances. The coagula-
tion system provides the immune system with a pos-
itive feedback by using substances with pro- and an-
ti-inflammatory effect. This well-established balance 
helps to limit pathogen dissemination (11,12). 
S. pyogenes is an obligatory pathogen for the 
human kind, which has evolved along with the hu-
man immune system. S. pyogenes is able to activate 
the coagulation system and then to avoid its defense 
mechanisms by promoting fibrinolysis (Fig. 1). Dur-
ing streptococcal infection, S. pyogenes stimulates 
platelet aggregation, M-protein-induced coupling of 
Fig. 1. Schematic representation of the interaction 
between Str. pyogenes and the host
Fig. 2. A schematic model of intrinsic and extrinsic 
pathway of hemostasis activation
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The primary phase of hemostasis is related to 
the formation of an FX complex, responsible for the 
activation of prothrombin (prothrombinase). It is re-
ported that during an infectious disease, an increased 
thromboplastin activity is observed, thus putting the 
patients at risk of disseminated intravascular coagu-
lation (DIC). Bacterial streptococcal toxins are able 
to induce sudden activation of the coagulation lead-
ing to increased level of thrombin due to the high fi-
brinogen and following intravascular coagulation on 
macro- and microlevel. The depletion of blood clot-
ting factors and the overwhelming fibrinolysis result 
in exhaustion of all hemostatic protective mecha-
nisms and development of acoagulability, hiding the 
risk of hemorrhagic syndromes (20,22).
2. Alteration in the second phase of hemostasis 
– coagulopathy 
During the second phase of hemostasis, the 
nonactive prothrombin is converted into active 
thrombin through FXа, FVа, Са and platelets FIIIа. 
Consequently, the syndrome of coagulopathy is de-
veloped (15, 20). Bacterial toxins play a key role in the 
pathophysiology of the second phase, because they 
are responsible for the toxic damage of liver. Altera-
tion of the synthetic and metabolic liver function in-
duces vitamin K deficiency, low level of prothrom-
bin, F VII, IX, X, reduced activity of proaccelerin. In 
infections running with toxic infectious syndrome, 
the synthesis of all plasma factors is compromised. 
The diminished stability of fibrin-stabilizing factor 
leads to reduced resistance of the blood clot and it 
becomes easily destroyable (20, 22). Corresponding-
ly, the inadequate function of the liver is a reason for 
abnormal fibrinogen synthesis and its level is highly 
reduced. Replenishment of the fibrinogen level is re-
alized by its extraction from the profibrin layer of the 
vascular wall. Consequently, the remodeled struc-
ture of the blood vessels leads to increased vascular 
permeability and leakage and an increase in hemor-
rhagic manifestations (20). 
3. Alteration in the third phase of coagulation – 
low levels of fibrinogen
The third phase of hemostasis is engaged in cat-
alytic transformation of fibrinogen into fibrin pep-
tides and monomers. These monomers have the abil-
ity to polymerize to a fibrin clot, which later con-
verts into stable fibrin with the assistance of FXIII. 
The pathological changes observed during the third 
phase of hemostasis are parenchymal damage of the 
liver and reduction of the level of fibrinogen (23).
Changes in Hemostasis Affecting Structural 
and Functional Components
Streptococcal toxins are able to induce bone 
marrow toxicity or an autoimmune process. In 2016, 
E. Fokina observed increased erythrocyte deform-
ability and decreased elasticity (24). Sjöbring et al. 
(2002) are pioneers in the elicitation of the strepto-
cocci-induced hemostatic changes. They proposed 
that M-protein of the cocci bonded with the plas-
ma fibrinogen. Then, the formed complex adheres 
to the GPIIb/IIIa fibrinogen receptors of platelets 
(25). Oehmcke et al. (2012) showed that the soluble 
M-protein was able to induce the release of procoag-
ulant particles from the monocytes – a mechanism 
activating both pathways of coagulation (26). Renné 
(2012) noticed that the induction of contact system 
of coagulation resulted in the release of proinflam-
matory peptides – kinins. Kinins are molecules able 
to induce anti-inflammatory reaction against strep-
tococci (27). Due to the pathogenic action of strepto-
coccal enzymes, a destruction of the protective lay-
er of heparan sulfate on the endothelium and an in-
crease in its prothrombogenic and adhesive abili-
ties can be seen (3,10). Erovichenkov et al. (2003) 
demonstrated an increased level of the biomarkers 
for vascular wall damage, such as collagen type III, 
IV, 5 -̀nucleotidase, in patients with erysipelas. It is 
thought that the contact with collagen is an inductor 
of release and aggregation of cellular elements in the 
blood, especially the platelets. 5 -̀ nucleotidase stimu-
lates the transformation of prothrombin into throm-
bin and fibrinogen into fibrin. It is established that 
in patients with erysipelas, substances with throm-
boplastic effect – damaged endothelial and epitheli-
al cells, erythrocytes, platelets and leucocytes - enter 
the blood circulation from the local site of inflam-
mation (6).
The activation of hemostasis in patients with 
erysipelas is combined depending on the source of 
thromboplastin (3). Due to the massive release of 
proinflammatory mediators, as a response to the in-
flammation, “cytokine storm” occurs. It leads to a 
number of immune reactions (8). 
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Radkevich (1973) first observed and described 
changes in hemostasis in erysipelas. His observa-
tion showed hypercoagulability running with suf-
ficiently increased level of fibrinogen, prothrom-
bin time, and decreased fibrinolytic activity (3,6). In 
1976, Dikov et al., investigated for the first time the 
changes in Bulgarian patients. Their results present-
ed hyperfibrinogenemia and prolongation of throm-
bin time. Russian authors proposed that hemocoag-
ulation changes were related to the development of 
a chronic thrombo-hemorrhagic syndrome, dimin-
ishing of blood clotting time, increase in the concen-
tration of fibrinogen, lowering the level of fibrinogen 
and antithrombin 3, cessation of Hageman-depen-
dent and induced streptokinase fibrinolysis (3). Stud-
ies of the cellular part of coagulation were conducted 
by Tcherkasov (1986). Other Russian authors shared 
their data consisting of reduced level of platelets and 
platelets factor IV, activation of procoagulant parts of 
hemostasis – increased level of fibrinogen, shortened 
aPTT, and increased fibrinolytic activity. The pro-
cess of activation of fibrinolysis is strongly activated 
in bullous-hemorrhagic erysipelas. The presence of 
DIC in the acute phase of inflammation depends on 
the severity of infection and on the condition of co-
agulation – hypo-/hypercoagulation. In primary fi-
brinolysis, the following changes are observed – in-
creased plasmin activity, reduced level of plasmino-
gen, normal level of platelets, and increased fibrin-
degrading products (6).
RESULTS
Activation of the coagulation system depends 
on the source of thromboplastin. Thus, the mecha-
nism of activation is often combined. Massive release 
of proinflammatory mediators is related to the so-
called “cytokine storm”, enabling the simultaneous 
activation of both immune and coagulation systems. 
In erysipelas, hemostatic changes manifest with hy-
percoagulability in the acute phase of disease (sig-
nificantly increased level of fibrinogen, prothrombin 
time, reduced fibrinolytic activity). These changes 
are probably associated with a thrombo-hemorrhag-
ic syndrome, shortening of the blood clotting time, 
increased concentration of fibrinogen, reduced level 
of antithrombin 3, cessation of Hageman-dependent 
and induced streptokinase fibrinolysis. There is a re-
duction in the level of platelets and the platelet factor. 
CONCLUSION
Coagulopathies are common findings in the 
pathogenesis of infectious diseases. They might be 
manifested as a clinical syndrome of the disease or 
as its complication. The spectrum of clinical find-
ings in coagulopathies is broad enough and may 
vary from microthrombosis to development of DIC 
– syndrome, hemorrhages, hemolytic-uremic syn-
drome or vasculitis. As there is an upward trend in 
the number of patients with hemorrhagic and bul-
lous-hemorrhagic erysipelas, as well as the presence 
of local and general predisposing factors, accompa-
nying diseases and/or immunomodulating and bio-
logical therapy, there arises the need to intensify the 
studies in hemostasis of erysipelas in order to com-
plete the diagnostic-therapeutic panel and prevent 
serious and irrevocable complications. 
In patients with streptococcal infections, the 
presence of coagulopathy is an important clinical 
finding. Determining the hemostatic deviations in 
erysipelas and the mechanisms of their induction al-
lows for planning in the direction of immune system 
modeling through the development of target thera-
py. Coagulopathy in erysipelas is closely connected 
to the inflammation response of etiological agent. 
Therefore, it is supposed that drugs affecting the im-
mune system may change the direction of coagula-
tion disorders. Low doses of antiplatelet drugs re-
duce the risk of multiorgan failure in septic patients. 
Blocking the activation of contact system may pre-
vent severe complications. Use of heparin during 
erysipelas shortens the recovery time. 
REFERENCES
1. Michael Y, Shaukat NM. Erysipelas. [Updated 
2019 Dec 20]. In: StatPearls [Internet]. Treasure Is-
land (FL): StatPearls Publishing; 2020 Jan-. Avail-
able from: https://www.ncbi.nlm.nih.gov/books/
NBK532247/.
2. Inghammar M, Rasmuussen M, Linder A. Re-
current erysipelas – risk factors and clinical pre-
sentations. BMC Infect Dis. 2014;14:270. doi: 
10.1186/1471-2334-14-270. 
3. Marina S, Kirov G. Erysipelas. Computer Art. 
1992. pp. 46-9. (In Bulgarian).
4. Pаhlman LI, Malmström E, Mörgelin M, Herwald 
H. M protein from Streptococcus pyogenes induces 
tissue factor expression and pro-coagulant activity 
Scripta Scientifica Medica, 2019;51(3):7-11
Medical University of Varna 11
Tsveta Kalinova, Yoanna Velevska, Sonya Márina
in human monocytes. Microbiology. 2011; 153(Pt. 
8): 2458–64. doi: 10.1099/mic.0.2006/003285-0.
5. Metzgar D, Zampolli A. The M-protein of group A 
streptococcus is a key virulence factor and a clini-
cally relevant strain identification marker. Viru-
lence. 2011; 2(5):402-12. doi: 10.4161/viru.2.5.16342. 
6. Shannon O, Herwald H, Oehmcke S. Modulation 
of the coagulation system during severe strepto-
coccal disease. Curr Top Microbiol Immunol. 2013; 
368:189-205. doi: 10.1007/82_2012_283.
7. Hynes W, Sloan M. Secreted extracellular virulence 
factors. Streptococcus pyogenes: Basic biology to 
clinical manifestation. Oklahoma City (OK): Uni-
versity of Oklahoma Health Sciences Center; 2016. 
pp. 1-22. 
8. Olsen RJ, Shelburne SA, Musser JM. Molecular 
mechanisms underlying group A streptococcal 
pathogenesis. Cell Microbiol. 2009; 11(1):1-12. doi: 
10.1111/j.1462-5822.2008.01225.x. 
9. Oehmcke S, Shannon O, Mörgelin M, Herwald H. 
Streptococcal M proteins and their role as viru-
lence determinants. Clin Chim Acta. 2010; 411(17-
18):1172–80. doi: 10.1016/j.cca.2010.04.032.
10. Sun H, Ringdahl U, Homeister JW, Fay WP, En-
gleberg NC. Plasminogen is a critical host patho-
genicity factor for group A streptococcal infec-
tion. Science. 2004; 305(5688):1283–6. doi: 10.1126/
science.1101245. 
11. Antoniak S. The coagulation system in host de-
fense. Res Pract Thromb Haemost. 2018; 2(3):549–
57. doi: 10.1002/rth2.12109.
12. Opal S. Interactions between coagulation and in-
flammation. Scand J Infect Dis. 2003; 35(9):545-54. 
doi:10.1080/00365540310015638. 
13. Margetic S. Inflammation and haemostasis. Bio-
chemia Medica. 2012; 22(1):49–62.
14. Nitzsche R, Rosenheinrich M, Kreikemeyer B, 
Oehmcke-Hecht S. Streptococcus pyogenes triggers 
activation of the human contact system by strep-
tokinase. Infect Immun. 2015; 83(8):3035–42. doi: 
10.1128/IAI.00180-15.
15. Loof TG, Deicke C, Medina E. The role of coagu-
lation/fibrinolysis during Streptococcus pyogenes 
infection. Front Cell Infect Microbiol. 2014; 4:128. 
doi: 10.3389/fcimb.2014.00128.
16. Chong AY, Blann AD, Lip GYH. Assessment of en-
dothelial damage and dysfunction: Observations in 
relation to heart failure. QJM - Mon J Assoc Phy-
sicians. 2003; 96(4): 253–67. doi:10.1093/qjmed/
hcg037. 
17. Periayah MH, Halim AS, Mat Saad AZ. Mecha-
nism action of platelets and crucial blood coagula-
tion pathways in hemostasis. Int J Hematol Oncol 
Stem Cell Res. 2017; 11(4): 319–27.
18. Linder A, Johansson l, Thulin P, Hertzén E, Mörge-
lin M, Christensson B, et al. Erysipelas caused by 
Group A Streptococcus activates the contact sys-
tem and induce the release of heparin-binding pro-
tein. J Invest Dermatol. 2010; 130(5):1365–72; doi: 
10.1038/jid.2009.437.
19. Inghammar M, Rasmuussen M, Linder A. Re-
current erysipelas – risk factors and clinical pre-
sentations. BMC Infect Dis. 2014; 14:270. doi: 
10.1186/1471-2334-14-270.
20. Genev G, Lahtariev St, Stoicheva M, Komitova R, 
Geneva M. Symptoms and syndromes in infectious 
diseases. Sofia: Meditsina i fizkultura; 2007. pp. 
167-168. (In Bulgarian). 
21. Loof TG, Schmidt O, Herwald H, Theopold U. Co-
agulation systems of invertebrates and vertebrates 
and their roles in innate immunity: the same side 
of two coins? J Innate Immun. 2011; 3(1):34–40. 
doi: 10.1159/000321641.
22. Gale JA. Current understanding of hemosta-
sis. Toxicol Pathol. 2011; 39(1):273–80. doi: 
10.1177/0192623310389474. 
23. Fokina E. Disfibrinogenemia and hidden hemolysis 
- indicators of hemorrhagic syndrome in erysipelas. 
Global J Med R Microbiol Pathol. 2016; 16(1):1-5. 
24. Fokina EG, Gerasimov AN. Prediction degree se-
verity of erysipelas: Risk index of hemorrhagic 
form of erysipelas. J Infec Dis Treat. 2016; 2:2. doi: 
10.21767/2472-1093.100026. 
25. Sjöbring U, Ringdahl U, Ruggeri ZM. Induc-
tion of platelet thrombi by bacteria and antibod-
ies. Blood. 2002; 100(13):4470–7. doi: 10.1182/
blood-2002-01-0069.
26. Oehmcke S, Mörgelin M, Malmström J, Linder A, 
Chew M, Thorlacius H, et al. Stimulation of blood 
mononuclear cells with bacterial virulence factors 
leads to the release of pro-coagulant and pro-in-
flammatory microparticles. Cell Microbiol. 2012; 
14(1):107–19. doi: 10.1111/j.1462-5822.2011.01705.x.
27. Renné T. The procoagulant and proinflammato-
ry plasma contact system. Semin Immunopathol. 
2012; 34(1):31–41. doi: 10.1007/s00281-011-0288-2.
